Evidence map›Paper›PMID 29925408›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

LncGPR107 drives the self-renewal of liver tumor initiating cells and liver tumorigenesis through GPR107-dependent manner.

Guanqun Huang, Hui Jiang, Ye Lin, Wuzheng Xia, Yuanwei Luo, Yanpeng Wu, Weilong Cai, Xinke Zhou, Xianhan Jiang

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Retraction Note: LncMAPK6 drives MAPK6 expressionand liver TIC self-renewal.Journal of experimental & clinical cancer research : CR · 2022
    Article
  3. The role of CD133 in hepatocellular carcinoma.Cancer biology & therapy · 2021
    Article
  4. LncRNAs link cancer stemness to therapy resistance.American journal of cancer research · 2021
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Guanqun HuangDepartment of general surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Hui JiangDepartment of Abdominal Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ye LinDepartment of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Wuzheng XiaDepartment of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Yuanwei LuoDepartment of general surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yanpeng WuDepartment of general surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Weilong CaiDepartment of general surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xinke ZhouDepartment of Abdominal Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. nihaeoj1465@126.com.
Xianhan JiangDepartment of Abdominal Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. pfd145628@126.com.
Guangzhou Medical University · CNGuangdong General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith self-renewal and differentiation properties, liver tumor initiating cells (TICs) are the reasons for tumor initiation, metastasis and drug resistance. G protein coupled receptors (GPCR) are critical modulators in many physiological and pathological processes. While, their roles in liver TICs are unknown.

methodsAn unbiased screening was performed using online-available data dataset. Liver TICs were sorted by FACS with surface marker CD133, or enriched by oncosphere formation. TIC self-renewal was examined by oncosphere formation and tumor initiation assay. Loss of function and gain of function assays were performed to examine the role of lncRNA. RNA pulldown, RNA immunoprecipitation, ChIP, western blot and double FISH were used explore the molecular mechanism of lncRNA.

resultsWe performed an unbiased screening for GPCR expression in liver cancers, and found GPR107 was the most highly expressed GPCR in liver cancer and liver TICs. GPR107 was essential for the self-renewal of liver TICs. The expression of GPR107 was regulated by a long noncoding RNA lncGPR107. LncGPR107 was also highly expressed in liver cancers and liver TICs. LncGPR107 drove the self-renewal of liver TICs through GPR107. Moreover, lncGPR107 recruited SRCAP complex to GPR107 promoter to drive its transcriptional activation. LncGPR107 depletion inhibited the binding of SRCAP complex and GPR107 promoter and subsequent GPR107 expression. Moreover, LncGPR107-SRCAP-GPR107 can be targeted for liver TIC elimination.

conclusionGPR107 was the most highly expressed GPCR in liver cancer and liver TICs. LncGPR107 participated in the transcriptional regulation of GPR107 in cis, through recruiting SRCAP remodeling complex to GPR107 promoter. This work revealed the important role of GPCR signaling in liver TIC self-renewal and added a new layer for liver TIC and GPCR regulation.

Indexed as

Gene Expression Regulation, NeoplasticRNA, Long NoncodingAgedAnimalsBiomarkers, TumorCarcinoma, HepatocellularCell Line, TumorCell Self RenewalCell Transformation, NeoplasticDisease Models, AnimalFemaleHeterograftsHumansLiver NeoplasmsMaleMiceBiomarkers, TumorGPR107 protein, humanReceptors, G-Protein-CoupledRNA, Long NoncodingGPR107Liver TICsLncGPR107Self-renewalSRCAP

Identifiers

PMID29925408
PMCPMC6011390
OpenAlexW2809683729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.